

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1.-10. (Cancelled)

11. (new) A method of improving anesthesia recovery comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a pharmaceutical composition of a NK-1 receptor antagonist; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

12. (new) The use of a composition comprising a NK-1 receptor antagonist; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug, in the manufacture of a medicament for improving anesthesia.

13. (new) A method of using an NK-1 receptor antagonist; a pharmaceutically acceptable salt thereof; a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug, for improving the quality of anesthetic recovery by reducing excessive vocalization and/or purposeless movement.


14. (new) A method or use according to Claim 13 wherein the NK-1 receptor antagonist is a compound comprising Formula I



I

wherein R² is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl, or a pharmaceutically acceptable salt thereof.

15. (new) A method or use according to Claim 14 wherein said compound comprises Formula Ia,



(2*S*,3*S*)-2-benzhydryl-*N*-(5-*tert*-butyl-2-methoxybenzyl)quinuclidin-3-amine, or a pharmaceutically acceptable salt thereof.

16. (new) The method or use according to Claim 15 wherein said compound is the citrate salt of the compound of Formula Ia.

17. (new) The method or use according to Claim 12 wherein said composition is parenterally, enterally or orally administered prior, during or after an administration of a general anesthesia.

18. (new) The method or use according to Claim 17 wherein said composition is administered parenterally.

19. (new) The method or use according to Claim 18 wherein said composition further comprises a pharmaceutically acceptable cyclodextrin.

20. (new) The method or use according to Claim 18 wherein the amount of the NK-1 antagonist is 0.01 mg/kg to 100 mg/kg of a patient's body weight.

21. (new) The method or use according to Claim 19 wherein the amount of the NK-1 antagonist is 0.01 mg/kg to 100 mg/kg of a patient's body weight.

22. (new) A pharmaceutical composition for improving anesthesia recovery comprising: a NK-1 receptor antagonist; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

23. (new) A pharmaceutical composition of Claim 22 where the NK-1 receptor is a compound comprising Formula I wherein R² is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl, or a pharmaceutically acceptable salt thereof.

24. (new) A pharmaceutical composition of Claim 23 where the NK-1 receptor is a composition comprising, (2*S*,3*S*)-2-benzhydryl-*N*-(5-*tert*-butyl-2-methoxybenzyl)quinuclidin-3-amine, or a pharmaceutically acceptable salt thereof.